Safety and efficacy of cladribine in patients discontinuing fingolimod due to elevated liver enzymes: FinClad study

Basit Öğe Kaydı
dc.contributor.authorSonmez, M.
dc.contributor.authorYetkin, M.
dc.contributor.authorMehdiyev, D. Arslan
dc.contributor.authorKoseoglu, M.
dc.contributor.authorMungan, S.
dc.contributor.authorKale, N.
dc.contributor.authorTerzi, M.
dc.date.accessioned2026-02-03T12:03:22Z
dc.date.available2026-02-03T12:03:22Z
dc.date.issued2025
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstract[No abstract available]
dc.identifier.issn1351-5101
dc.identifier.issn1468-1331
dc.identifier.urihttps://hdl.handle.net/20.500.12428/35054
dc.identifier.volume32
dc.identifier.wosWOS:001628319700011
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofEuropean Journal of Neurology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20260130
dc.titleSafety and efficacy of cladribine in patients discontinuing fingolimod due to elevated liver enzymes: FinClad study
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu